Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Vytorin (correction)

Executive Summary

Print DTC ads emphasizing the ability of Merck/Schering-Plough's Vytorin to reduce LDL-cholesterol levels began running on March 30. Following an FDA request in January, the ads carry the disclaimer that "Vytorin has not been shown to reduce heart attacks or strokes more than Zocor alone." A recent article mistakenly said the statement is being included in DTC ads as a result of safety signals identified in the ENHANCE trial (1"The Pink Sheet," April 14, 2008, In Brief). Furthermore, no new safety signals were associated with Vytorin treatment in the ENHANCE trial

You may also be interested in...



Vytorin ads Enhance warning language

DTC print advertisements for Merck/Schering-Plough's Vytorin (ezetimibe/simvastatin) began carrying a bolded warning March 30 to highlight safety signals identified in the ENHANCE study. The print ad, "Do you have high LDL (bad) cholesterol," ran through April 6 and contained a statement that "Vytorin has not been shown to reduce heart attacks or strokes more than Zocor alone." The statement also will appear in broadcast ads for the drug, the firm tells "The Pink Sheet." The Vytorin buzz shares the DTC spotlight with Pfizer's ads for Lipitor, which gained attention for its celebrity endorsement by Robert Jarvick last month (1"The Pink Sheet," March 3, 2008, p. 10)

Prop 65 Warnings Intended For Small Spaces But Used On Luggage? California Proposes Limits

California proposes limiting short-form Prop 65 warnings to products with 5 inches or less of labeling space, while prohibiting their use in online and catalog warnings. The number of products with the warnings, used even on vacuum cleaners, luggage and guitars, has made tracking them impossible.

EU’s SCCS Finds Endocrine-Disrupting Evidence Inconclusive In UV Filter Reassessments

While endocrine-disrupting evidence was inconclusive, the Scientific Committee on Consumer Safety recommends more conservative limits on use of homosalate, octocrylene and benzophenone-3 in cosmetic products compared with current requirements under the European Cosmetics Product Regulation.

UsernamePublicRestriction

Register

OM006922

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel